Product Center
Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-13
- Views:
(Summary description)Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
Trivalent and quadrivalent influenza virus subunit vaccines (adjuvants) have entered phase I clinical trials as scheduled
(Summary description)Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-11-13 09:02
- Views:
Recently, Jiangsu Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (hereinafter referred to as "Yither Bio") jointly applied for the Phase I clinical trials of a new drug, "Influenza Virus Subunit Vaccine (Adjuvant)" and "Tetravalent Influenza Virus Subunit Vaccine (Adjuvant)", which have been successfully launched in Hubei. These two vaccine research and development achievements are steadily being realized as company performance, and also mark a solid step towards the goal of providing the most accurate coverage for different age groups and different demand groups in the company's sub unit influenza vaccine product pipeline.
At present, influenza virus remains one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. Compared to other age groups, the elderly have a higher infection rate and a greater risk of severe illness and death after contracting the flu, which increases with age. WHO and the Chinese Center for Disease Control and Prevention recommend elderly people as one of the priority groups for influenza vaccination.
Adjuvant containing influenza virus subunit vaccine is a flu vaccine developed by the company in response to the vaccination needs of different populations and WHO's recommendations for flu vaccines. It is suitable for the elderly aged 65 and above, using the company's mature platform technology and new adjuvants. Preclinical studies have shown that influenza virus subunit vaccines containing adjuvants can significantly increase the body's antibody levels and neutralizing antibody titers, and have significant advantages in enhancing immune response capabilities, providing the optimal choice for elderly populations to cope with influenza.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
